Posts

GSK's $700M Alector Partnership Ends After Nivisnebart Alzheimer's Drug Fails Phase 2 Trial

on
GSK and Alector halted the phase 2 PROGRESS-AD trial of nivisnebart (AL101/GSK4527226), an anti-sortilin 1 antibody, after an interim futility analysis showed it was unlikely to meet the primary endpoint of slowing disease progression in early Alzheimer's patients. 1 The trial involved 367 participants randomized to one of two doses or placebo; the drug aimed to elevate progranulin levels to support brain neurons and microglia. 1 This failure marks the second setback for the 2021 GSK-Alector partnership, which included a $700M upfront payment, following latozinemab's phase 3 failure in frontotemporal dementia. 1 5 Analysts at TD Cowen state the result effectively ends the GSK-Alector partnership. 1 Alector's prior AbbVie-partnered Alzheimer's candidate also failed in 2024. 1 Sources: 1. https://www.fiercebiotech.com/biotech/gsks-700m-alector-bet-blows-alzheimers-drug-flunks-phase-2 5. https://lifescivoice.com/alector-latozinemab-development-failure-ftd/

Eli Lilly Touts Strong Early Launch of Foundayo Obesity Pill Despite Lagging Behind Novo's GLP-1

on

Bristol Myers Squibb's Pipeline Focus in Pivotal 2026

on

Regeneron's Eylea Quarterly Sales Drop Below $1B for First Time in 8 Years Amid Competition and Shift to High-Dose Version

on

BeOne Medicines Signs $2B Deal for Preclinical Trispecific Antibody Option with China's Huahui Health

on

Biogen Pursues Early-Stage Assets to Build Next Generation Growth Pipeline

on

Novartis CEO Calls for 'Complete Rethink' on Europe's Drug Pricing Policies

on

Insilico's Rentosertib Inhalation Solution Receives IND Clearance for World's First AI-Driven Direct-to-Lung Clinical Study

on

Biogen's Post-Apellis Strategy: Expanding Early-Stage Pipeline to Drive Next-Generation Growth

on

AbbVie Reports Strong Skyrizi Sales Amid Wall Street Concerns Over J&J's Icotyde Pill

on

Pfizer's Elrexfio Meets Phase III Primary Endpoint in Multiple Myeloma, Positioning Drug for Earlier-Line Use

on

Biopharma Bites: AstraZeneca's Camizestrant Faces FDA ODAC Scrutiny Amid Trial Design Concerns

on

AstraZeneca Posts 20% Jump in Cancer Drug Sales Amid Pipeline Challenges

on